Abiopharma

🔍 Reynolds Shelley (Executive)

Company: AMAZON COM INC (AMZN)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 1,800 shares of Common Stock, par value $.01 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 121,580.00 | transaction_form_type: 4
• Acquired 543 shares of Common Stock, par value $.01 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 122,123.00 | transaction_form_type: 4
• Sold 675 shares of Common Stock, par value $.01 per share at $257.7656 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 121,448.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 780 shares of Common Stock, par value $.01 per share at $258.5812 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,668.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 888 shares of Common Stock, par value $.01 per share at $260.3252 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 119,780.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Holds 0 shares of Common Stock, par value $.01 per share (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: Amazon.com 401(k) plan account | shares_owned_after: 2,655.72
• Sold 1,800 shares of Restricted Stock Unit Award (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2028-02-21 | Exercise: 2023-05-21 | equity_swap_involved: 0 | shares_owned_after: 9,040.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 543 shares of Restricted Stock Unit Award (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2030-02-21 | Exercise: 2024-08-21 | equity_swap_involved: 0 | shares_owned_after: 14,826.00 | transaction_form_type: 4 | Footnotes: F5, F7

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/11/2025.
• F2: Represents the weighted average sale price. The highest price at which shares were sold was $258.11 and the lowest price at which shares were sold was $257.19.
• F3: Represents the weighted average sale price. The highest price at which shares were sold was $258.98 and the lowest price at which shares were sold was $258.23.
• F4: Represents the weighted average sale price. The highest price at which shares were sold was $261.00 and the lowest price at which shares were sold was $260.03.
• F5: Converts into Common Stock on a one-for-one basis.
• F6: This award vests based upon the following vesting schedule: 80 shares on each of May 21, 2023, August 21, 2023, and November 21, 2023; 60 shares on February 21, 2024; 360 shares on each of May 21, 2024 and August 21, 2024; 340 shares on each of November 21, 2024 and February 21, 2025; 560 shares on each of May 21, 2025 and August 21, 2025; 540 shares on each of November 21, 2025 and February 21, 2026; 1,820 shares on May 21, 2026; 1,800 shares on each of August 21, 2026, November 21, 2026, and February 21, 2027; and 1,360 shares on each of May 21, 2027, August 21, 2027, November 21, 2027, and February 21, 2028.
• F7: This award vests based upon the following vesting schedule: 2,772 shares on each of August 21, 2024 and November 21, 2024; 2,771 shares on February 21, 2025; 355 shares on each of May 21, 2025, August 21, 2025, November 21, 2025, and February 21, 2026; 543 shares on each of May 21, 2026, August 21, 2026, and November 21, 2026; 542 shares on February 21, 2027; 682 shares on each of May 21, 2027 and August 21, 2027; 681 shares on each of November 21, 2027 and February 21, 2028; 1,569 shares on each of May 21, 2028, August 21, 2028, November 21, 2028, and February 21, 2029; 1,185 shares on each of May 21, 2029, August 21, 2029, and November 21, 2029; and 1,184 shares on February 21, 2030.
• REMARKS: The reporting person undertakes to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares transacted at each price, with respect to all transactions reported on this Form 4.